Please see below for a list of search results.
The HTA’s high-level aims, objectives and high-level milestones and deliverables for 2019/20 are set out in this section. This information is supported by our key performance indicators (KPIs) at the end of this Plan, which set out how we will measure whether we are achieving those aims.
This business plan sets out our ambitions for 2019/20. The HTA operates a continuous business planning process - we maintain a pipeline of proposed business activities over a three-year period, which allows us to adapt and plan in response to changes in our operating environment.
This business plan sets out our priorities and objectives for the 2019/20 business year. Please use the navigation bar on the left to browse.
Our regulatory approach aims to be right-touch and in line with the principles of better regulation and the Regulators’ Code. This means that we primarily focus our regulation and resources on areas that involve an inherently greater risk to patient safety and public confidence if standards are...
To ensure that the HTA’s regulatory approach remains relevant, we actively prepare for the future. We do this through our development activities.
Our strategic approach is based on right-touch regulation. This means being clear on the risks we are regulating, being proportionate and targeted in regulating those risks, taking into account the role of professional bodies and other regulators, and using the minimum necessary direct...
In 2017 the HTA undertook a fundamental evaluation of the extent to which our strategic approach protects public and professional confidence in the proper use, and quality and safety of, human tissues, cells and organs.